Delivery Order SPE2DB22D3501-SPE2DB25FXH22
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $20,776.45 on June 11, 2025, for the supply of Abiraterone Acetate 500 mg tablets (60-count). This is a firm fixed price, non-competitive delivery order with an ultimate completion date of June 12, 2025, to be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with DLA. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $104,283.60 to AmerisourceBergen Drug Corp for the supply of Abiraterone Acetate 250 mg tablets (120-count units). This competitively awarded, firm fixed-price contract was executed on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Abiraterone Acetate 500 mg tablets (60 count) with a ceiling value of $13,456.36. This is a firm fixed price delivery order with no set-aside designation, completed competitively, with a performance location in Conshohocken, Pennsylvania and an ultimate completion date of September 10, 2025. The award represents a single delivery order issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,112.98 to AmerisourceBergen Drug Corp for the supply of Abiroterone Acetate 250 mg tablets (120-count package). This is a firm fixed price contract with an ultimate completion date of September 12, 2025, and was awarded on September 11, 2025. The contract carries no set-aside designation, indicating it was competitively awarded through open procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Abiraterone Acetate 500 mg tablets (60-count) with a ceiling value of $21,098.76. This firm fixed-price delivery order, which has an ultimate completion date of June 3, 2025, carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a competitively awarded contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Abiraterone Acetate 250 mg tablets (120-count units) valued at $1,488.86. This firm fixed-price delivery order is expected to reach completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the vendor's capability to meet...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Abiraterone Acetate 500 mg, valued at $7,898.12 under a firm fixed price contract. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Abiraterone Acetate 250 mg tablets (120-count) with a ceiling value of $1,783.60. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract through open competition. The order is scheduled for completion by July 18, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,835.88 delivery order to AmerisourceBergen Drug Corp for Abiroterone Acetate 250 mg tablets (30-count unit dose packaging) with a completion date of July 31, 2025. This competitive award, issued on July 30, 2025, represents a firm fixed price delivery against AmerisourceBergen's larger indefinite delivery contract vehicle. The pharmaceutical product will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. No set-aside designation was...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Abiroterone Acetate 250 mg tablets (120-count) with a contract value of $28,842.31. This competitively awarded, firm fixed-price delivery order is classified as non-set-aside and is scheduled for completion by August 26, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXH22Delivery Order
The Defense Logistics Agency awarded a $1,745.56 delivery order to AmerisourceBergen Drug Corp for Abiraterone Acetate 250 mg tablets (120-count supply) under a firm fixed price contract. The award was made on September 12, 2025, with an ultimate completion date of September 15, 2025. This non-set-aside order represents a competitive award to support federal medical procurement needs, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism. The parent contract enables AmerisourceBergen to supply a wide range of pharmaceutical products, vaccines, medical devices, and specialized healthcare commodities to support military healthcare systems and other federal customers including the Defense Health Agency and U.S. Coast Guard. Abiroterone acetate, an androgen biosynthesis inhibitor used in cancer treatment, represents the type of specialized pharmaceutical product critical to military medical supply chains that the company delivers through this strategic contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/12/25 |